If you’re on the fence about investing in Integer Holdings Corporation or Bausch + Lomb Corporation because you’re not sure ... and contact lens care products comprising over-the-counter eye drops, ...
Brent Saunders, Bausch and Lomb CEO, joins 'Money Movers' to discuss how Saunders has changed the portfolio in his time as ...
Bausch + Lomb acquired Whitecap Biosciences, including its two therapies for potential use in glaucoma and geographic atrophy ...
InflammX’s pipeline includes an orally dosed therapeutic candidate targeting intermediate age-related macular degeneration ...
City Therapeutics will develop a novel RNAi clinical candidate toward a specific disease target for intravitreal ...
City Therapeutics and Bausch + Lomb have entered into a strategic collaboration focused on the development of an RNA ...
Bausch + Lomb (BLCO) announced an affiliate has acquired Whitecap Biosciences which is currently developing two innovative therapies for ...
Bausch + Lomb (BLCO) announced the commercial launch of the enVista Aspire monofocal and toric intraocular lenses in the European Union after ...
Bausch + Lomb moved to bolster the eye-care company's pipeline of clinical-stage offerings with the acquisition of Whitecap Biosciences, a firm developing two therapies for potential use in glaucoma ...
VAUGHAN, Ontario, January 13, 2025--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better ...
Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the commercial launch of the enVista Aspire ...